A novel approach to first-trimester screening for early pre-eclampsia combining serum PP13 and Doppler ultrasound

Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK.
Ultrasound in Obstetrics and Gynecology (Impact Factor: 3.14). 01/2005; 27(1):13-17. DOI: 10.1002/uog.2686
Source: PubMed

ABSTRACT To investigate the value of maternal serum placental protein 13 (PP-13) measurement and uterine artery Doppler during first-trimester screening in the prediction of early pre-eclampsia.
This was a nested case-control prospective study of pregnancies at 11 + 0 to 13 + 6 weeks of gestation. The pulsatility index (PI) of blood flow in the uterine arteries and the maternal serum concentration of PP-13 were measured in 10 women who went on to develop pre-eclampsia that necessitated delivery before 34 weeks, and in 423 unaffected women. Results were expressed as multiples of the gestation-specific median in controls (MoM). A logistic regression model was used to predict detection and false-positive rates.
In the cases that developed pre-eclampsia requiring delivery before 34 weeks, compared with the unaffected pregnancies, the median uterine artery PI was higher (1.43 MoM) and the median serum PP-13 level was lower (0.07 MoM; P < 0.001, Wilcoxon rank sum test for both). Modeling predicted that for a 90% detection rate of pre-eclampsia requiring delivery before 34 weeks, the false-positive rate of screening by PP-13 was 12%, by uterine artery PI was 31% and by a combination of the two methods was 9%. A policy of contingency screening, whereby all women are screened by maternal serum PP-13 and only the 14% at highest risk are then screened by Doppler, achieved a detection rate of 90% with an overall false-positive rate of 6%.
Effective screening for pre-eclampsia requiring delivery before 34 weeks can potentially be provided by assessment of a combination of maternal serum PP-13 and uterine artery Doppler in the first trimester of pregnancy.


Available from: Marei Sammar, May 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is an increasing interest in first trimester risk prediction models for pre-eclampsia. To systematically review and critically assess the building and reporting of methods used to develop first trimester risk prediction models for pre-eclampsia. Search of PubMed and EMBASE databases from inception to July 2013. Logistic regression model for predicting the risk of pre-eclampsia in the first trimester, including uterine artery Doppler among independent variables. We extracted information on study design, outcome definition, participant recruitment, sample size and number of events, risk predictors and their selection and treatment, model-building strategies, missing data, overfitting and validation. The initial search identified 80 articles. A total of 24 studies were eligible for review, from which 38 predictive models were identified. The median number of study participants was 697 [interquartile range (IQR) 377- 5126]. The median number of cases of pre-eclampsia per model was 37 (IQR 19-97). The median number of risk predictors was 5 (IQR 3.75-7). In 22% of the models, the number of events per variable was fewer than the commonly recommended value of 10 events per predictor; this proportion increased to 94% in models for early pre-eclampsia. Treatment and handling of missing data were not reported in 37 models. Only three models reported model validation. We found frequent methodological deficiencies in studies reporting risk prediction models for pre-eclampsia. This may limit their reliability and validity. © 2015 Royal College of Obstetricians and Gynaecologists.
    BJOG An International Journal of Obstetrics & Gynaecology 03/2015; DOI:10.1111/1471-0528.13334 · 3.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During pregnancy close interactions between the maternal system and the fetal system via the placenta exist that result in a powerful crosstalk between both individuals. Looking for predictive biomarkers in maternal blood is extremely difficult because of this crosstalk as such markers may be derived from only maternal sources, only placental sources or both. In particular, the concentrations of markers derived from both sources may vary because of the huge variety of reasons and sources. During the last decade this has misled a number of scientists and clinicians who tried to decipher the sources of markers and the impact of the placenta and/or the maternal vascular system. A few examples for predictive biomarkers are presented, the placenta-specific marker placental protein 13 (PP13) and the angiogenic marker PlGF being released from both mother and placenta. Finally, a further reason why biomarkers may not be successful in predicting all cases of preeclampsia is that different causative routes lead to the development of preeclampsia. The differences in the development of preeclampsia not only explain why markers may or may not have a predictive value, but also why some mothers and/or children may display long-term effects later in life. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    Journal of Reproductive Immunology 12/2014; 108. DOI:10.1016/j.jri.2014.11.003 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Normal trophoblast growth is one of the more important stages of early pregnancy that has a deciding factor on its later development and normal outcome. Identifying pregnant women who have a high risk of complications connected to hypertension during pregnancy is currently one of the most important tasks of perinatal medicine. Abnormal placentation is related not only to the appearance of preeclampsia, but also to many other complications, such as premature placental abruption, intrauterine fetal demise, and intrauterine growth restriction. Preeclampsia and eclampsia are one of the major causes of maternal morbidity and mortality and appear in about 5% of all pregnancies. Clinical symptoms are a far-removed consequence of abnormal placentation. When they become visible, it is definitely too late for preventive action, and there is essentially no effective treatment. New research data suggests that a chance of prophylactic intervention might exist as early as in the first trimester of the pregnancy. One of the clinically documented possibilities is to apply low doses of acetylsalicylic acid before the 16th week of gestation. Despite the great importance of the placenta in the physiology of pregnancy, not much attention has been paid to the way it functions. This paper reviews selected biochemical and biophysical markers which are, or could be, used in clinical practice in the future.
    Neuro endocrinology letters 11/2014; 35(6):440-444. · 0.94 Impact Factor